UEG Week Recordings UEG Week Posters Online courses Guidelines Mistakes in... Podcasts Webinars
new
Gut Guide online
Visit ueg.eu Create myUEG account Log In
Visit ueg.eu Create myUEG account Log In

Filters:

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in liver transplantation and how to avoid them

Alberto Zanetto, Patrizia Burra

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Adam R, et al. 2018 Annual report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293–1317. [Link]
2.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433–485. [Link]
3.
Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144–1165. [Link]
4.
Russo FP, Ferrarese A and Zanetto A. Recent advances in understanding and managing liver transplantation. F1000Res 2016; 5. [Link]
5.
Toniutto P, et al. Current challenges and future directions for liver transplantation. Liver Int 2017; 37: 317–327. [Link]
6.
European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402. [Link]
7.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64: 179–202. [Link]
8.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047–1081. [Link]
9.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154–181. [Link]
10.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. [Link]
11.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. [Link]
12.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70: 172–193. [Link]
13.
Burra P, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138–148. [Link]
14.
Testino G, et al. Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020; 52: 21–32. [Link]
15.
Kotlyar DS, et al. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103: 734–743. [Link]
16.
Donckier V, et al. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol 2014; 60: 866–871. [Link]
17.
Burra P and Germani G. Transplantation for acute alcoholic hepatitis. Clin Liver Dis 2017; 9: 141–143. [Link]
18.
Donnadieu-Rigole H, et al. Integration of an Addiction Team in a Liver Transplantation Center. Liver Transpl 2019; 25: 1611–1619. [Link]
19.
Erard-Poinsot D, et al. Natural history of recurrent alcohol-related cirrhosis after liver transplantation: fast and furious. Liver Transpl 2020; 26: 25–33. [Link]
20.
Lucey MR, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628–637. [Link]
21.
Burra P, et al. Long-term medical and psycho-social evaluation of patients undergoing orthotopic liver transplantation for alcoholic liver disease. Transpl Int 2000; 13 (Suppl 1): S174–S178. [Link]
22.
Tandon P, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009; 104: 1700–1706. [Link]
23.
Burra P, et al. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017; 49: 241–253. [Link]
24.
Mathurin P, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790–1800. [Link]
25.
Cross TJ, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382–1388. [Link]
26.
Lipshutz GS, et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775–781. [Link]
27.
Durand F, et al. Age and liver transplantation. J Hepatol 2019; 70: 745–758. [Link]
28.
Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357. [Link]
29.
Nair S, Verma S and Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105–109. [Link]
30.
Hakeem AR, et al. Increased morbidity in overweight and obese liver transplant recipients: a single–center experience of 1,325 patients from the United Kingdom. Liver Transpl 2013; 19: 551–562. [Link]
31.
Leonard J, et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667–672. [Link]
32.
Kim, HY and Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015; 21: 7637–7647. [Link]
33.
Ooi PH, et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019; 25: 1422–1438. [Link]
34.
Pinto Dos Santos D, et al. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. Eur J Gastroenterol Hepatol Epub ahead of print, November 8, 2019. doi: 10.1097/MEG.0000000000001552. [Link]
35.
Carey EJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23: 625–633. [Link]
36.
Lai JC, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66: 564–574. [Link]
37.
Berzigotti A, Saran U and Dufour J-F. Physical activity and liver diseases. Hepatology 2016; 63: 1026–1040. [Link]
38.
Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699. [Link]
39.
Costentin CE, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation? Hepatology 2019; 69: 1324–1336. [Link]
40.
Duvoux C, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986–994.e3. [Link]
41.
Cillo U, et al. A multistep consensus-based approach to organ allocation in liver transplantation: toward a 'blended principle model'. Am J Transplant 2015; 15: 2552–2561. [Link]
42.
Zanetto A, et al. Mortality in liver transplant recipients with portal vein thrombosis — an updated meta-analysis. Transpl Int 2018; 31: 1318–1329. [Link]
43.
Senzolo M, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol 2018; 9: 176. [Link]
44.
Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61: 660–667. [Link]
45.
D'Amico G, De Franchis R and Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599–612. [Link]
46.
Zanetto A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017; 49: 440–445. [Link]
47.
Rodriguez-Castro KI, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31: 34–42. [Link]
48.
Zanetto A and Senzolo M. Management of thrombosis in liver transplant candidate. In: Bezinover D and F Saner FH (Eds). Critical Care for Potential Liver Transplant Candidates. 2019; New York: Springer International Publishing. pp 119–146.
49.
Loffredo L, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153: 480–487.e1. [Link]
50.
Senzolo M, et al. Portal vein thrombosis in decompensated cirrhosis: rationale for treatment. Clin Transl Gastroenterol 2019; 10: e00026. [Link]
51.
Tripodi A and Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147–156. [Link]
52.
Lisman T, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53–61. [Link]
53.
Rijken DC, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116–2122. [Link]
54.
Russo FP, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int 2018; 38: 2210–2218. [Link]
55.
Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis 2016; 48: 455–467. [Link]
56.
Intagliata NM and Caldwell SH. Changes in hemostasis in liver disease. J Hepatol 2017; 67: 1332–1333. [Link]
57.
DeAngelis GA, et al. Bleeding risk and management in interventional procedures in chronic liver disease. J Vasc Interv Radiol 2016; 27: 1665–1674. [Link]
58.
O'Leary JG, et al. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology 2019; 157: 34–43.e1. [Link]
59.
Lisman, T. Interpreting hemostatic profiles assessed with viscoelastic tests in patients with cirrhosis. J Clin Gastroenterol 2020; 54: 389–391. [Link]
60.
Mallett S, et al. Thrombin generation tests and viscoelastic testing in cirrhosis: comparing apples and oranges? Eur J Anaesthesiol 2017; 34: 36–37. [Link]
61.
De Pietri L, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566–573. [Link]
62.
Lucey MR, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3–26. [Link]
63.
Watt KD and Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199–206. [Link]
64.
Madhwal S, et al. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl 2012; 18: 1140–1146. [Link]
65.
Desai S, Hong JC and Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors incidence and management. Liver Int 2010; 30: 948–957. [Link]
66.
Germani G, et al. Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. Dig Liver Dis 2020; 52: e46–e71 [Link]
67.
Bernal W, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013; 59: 74–80. [Link]
68.
Gimson AE, et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288–294. [Link]
69.
Bernal W, et al. Acute liver failure. Lancet 2010; 376: 190–201. [Link]

Abstract

Topics

Hepatobiliary Surgery

Citation

Burra P and Zanetto A. Mistakes in liver transplantation and how to avoid them. UEG Education 2020; 2020: 1–6.

Published

2020

More Like This:

From Vienna to Berlin: What inspired us last year at UEG Week

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre Pradeep Mundre, Egle Dieninyte - Misiune

Mistakes in coeliac disease diagnosis and how to avoid them

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio Roberto De Giorgio, Giacomo Caio, Umberto Volta

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude C. Janneke van der Woude, Shannon Kanis

Complications in endoscopy with Srisha Hebbar Part 1

Complications in endoscopy with Srisha Hebbar Part 1

Pradeep Mundre Pradeep Mundre, Srisha Hebbar

Mistakes in enteral stenting and how to avoid them

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

UEG Podcast Episode
UEG Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

From Vienna to Berlin: What inspired us last year at UEG Week

Egle Dieninyte - Misiune, Pradeep Mundre

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Published

2025

More Like This:

From Vienna to Berlin: What inspired us last year at UEG Week

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre Pradeep Mundre, Egle Dieninyte - Misiune

Mistakes in coeliac disease diagnosis and how to avoid them

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio Roberto De Giorgio, Giacomo Caio, Umberto Volta

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude C. Janneke van der Woude, Shannon Kanis

Complications in endoscopy with Srisha Hebbar Part 1

Complications in endoscopy with Srisha Hebbar Part 1

Pradeep Mundre Pradeep Mundre, Srisha Hebbar

Mistakes in enteral stenting and how to avoid them

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio 1, Giacomo Caio 1, Umberto Volta 1

Affiliations

1 University of Bologna, Italy

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Adam R, et al. 2018 Annual report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293–1317. [Link]
2.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433–485. [Link]
3.
Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144–1165. [Link]
4.
Russo FP, Ferrarese A and Zanetto A. Recent advances in understanding and managing liver transplantation. F1000Res 2016; 5. [Link]
5.
Toniutto P, et al. Current challenges and future directions for liver transplantation. Liver Int 2017; 37: 317–327. [Link]
6.
European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402. [Link]
7.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64: 179–202. [Link]
8.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047–1081. [Link]
9.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154–181. [Link]
10.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. [Link]
11.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. [Link]
12.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70: 172–193. [Link]
13.
Burra P, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138–148. [Link]
14.
Testino G, et al. Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020; 52: 21–32. [Link]
15.
Kotlyar DS, et al. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103: 734–743. [Link]
16.
Donckier V, et al. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol 2014; 60: 866–871. [Link]
17.
Burra P and Germani G. Transplantation for acute alcoholic hepatitis. Clin Liver Dis 2017; 9: 141–143. [Link]
18.
Donnadieu-Rigole H, et al. Integration of an Addiction Team in a Liver Transplantation Center. Liver Transpl 2019; 25: 1611–1619. [Link]
19.
Erard-Poinsot D, et al. Natural history of recurrent alcohol-related cirrhosis after liver transplantation: fast and furious. Liver Transpl 2020; 26: 25–33. [Link]
20.
Lucey MR, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628–637. [Link]
21.
Burra P, et al. Long-term medical and psycho-social evaluation of patients undergoing orthotopic liver transplantation for alcoholic liver disease. Transpl Int 2000; 13 (Suppl 1): S174–S178. [Link]
22.
Tandon P, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009; 104: 1700–1706. [Link]
23.
Burra P, et al. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017; 49: 241–253. [Link]
24.
Mathurin P, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790–1800. [Link]
25.
Cross TJ, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382–1388. [Link]
26.
Lipshutz GS, et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775–781. [Link]
27.
Durand F, et al. Age and liver transplantation. J Hepatol 2019; 70: 745–758. [Link]
28.
Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357. [Link]
29.
Nair S, Verma S and Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105–109. [Link]
30.
Hakeem AR, et al. Increased morbidity in overweight and obese liver transplant recipients: a single–center experience of 1,325 patients from the United Kingdom. Liver Transpl 2013; 19: 551–562. [Link]
31.
Leonard J, et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667–672. [Link]
32.
Kim, HY and Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015; 21: 7637–7647. [Link]
33.
Ooi PH, et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019; 25: 1422–1438. [Link]
34.
Pinto Dos Santos D, et al. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. Eur J Gastroenterol Hepatol Epub ahead of print, November 8, 2019. doi: 10.1097/MEG.0000000000001552. [Link]
35.
Carey EJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23: 625–633. [Link]
36.
Lai JC, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66: 564–574. [Link]
37.
Berzigotti A, Saran U and Dufour J-F. Physical activity and liver diseases. Hepatology 2016; 63: 1026–1040. [Link]
38.
Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699. [Link]
39.
Costentin CE, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation? Hepatology 2019; 69: 1324–1336. [Link]
40.
Duvoux C, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986–994.e3. [Link]
41.
Cillo U, et al. A multistep consensus-based approach to organ allocation in liver transplantation: toward a 'blended principle model'. Am J Transplant 2015; 15: 2552–2561. [Link]
42.
Zanetto A, et al. Mortality in liver transplant recipients with portal vein thrombosis — an updated meta-analysis. Transpl Int 2018; 31: 1318–1329. [Link]
43.
Senzolo M, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol 2018; 9: 176. [Link]
44.
Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61: 660–667. [Link]
45.
D'Amico G, De Franchis R and Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599–612. [Link]
46.
Zanetto A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017; 49: 440–445. [Link]
47.
Rodriguez-Castro KI, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31: 34–42. [Link]
48.
Zanetto A and Senzolo M. Management of thrombosis in liver transplant candidate. In: Bezinover D and F Saner FH (Eds). Critical Care for Potential Liver Transplant Candidates. 2019; New York: Springer International Publishing. pp 119–146.
49.
Loffredo L, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153: 480–487.e1. [Link]
50.
Senzolo M, et al. Portal vein thrombosis in decompensated cirrhosis: rationale for treatment. Clin Transl Gastroenterol 2019; 10: e00026. [Link]
51.
Tripodi A and Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147–156. [Link]
52.
Lisman T, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53–61. [Link]
53.
Rijken DC, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116–2122. [Link]
54.
Russo FP, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int 2018; 38: 2210–2218. [Link]
55.
Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis 2016; 48: 455–467. [Link]
56.
Intagliata NM and Caldwell SH. Changes in hemostasis in liver disease. J Hepatol 2017; 67: 1332–1333. [Link]
57.
DeAngelis GA, et al. Bleeding risk and management in interventional procedures in chronic liver disease. J Vasc Interv Radiol 2016; 27: 1665–1674. [Link]
58.
O'Leary JG, et al. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology 2019; 157: 34–43.e1. [Link]
59.
Lisman, T. Interpreting hemostatic profiles assessed with viscoelastic tests in patients with cirrhosis. J Clin Gastroenterol 2020; 54: 389–391. [Link]
60.
Mallett S, et al. Thrombin generation tests and viscoelastic testing in cirrhosis: comparing apples and oranges? Eur J Anaesthesiol 2017; 34: 36–37. [Link]
61.
De Pietri L, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566–573. [Link]
62.
Lucey MR, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3–26. [Link]
63.
Watt KD and Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199–206. [Link]
64.
Madhwal S, et al. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl 2012; 18: 1140–1146. [Link]
65.
Desai S, Hong JC and Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors incidence and management. Liver Int 2010; 30: 948–957. [Link]
66.
Germani G, et al. Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. Dig Liver Dis 2020; 52: e46–e71 [Link]
67.
Bernal W, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013; 59: 74–80. [Link]
68.
Gimson AE, et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288–294. [Link]
69.
Bernal W, et al. Acute liver failure. Lancet 2010; 376: 190–201. [Link]

Abstract

Coeliac disease is an autoimmune disorder triggered by gluten, which activates an immune reaction against the autoantigen tissue transglutaminase (TG2) in genetically predisposed subjects. Genetic susceptibility to coeliac disease has been proven by its close linkage with major histocompatibility complex (MHC) class II human leukocyte antigen (HLA) DQ2 and DQ8 haplotypes. The identification of biomarkers for coeliac disease (e.g. endomysial antibodies [EmA] and antibodies to TG2 [anti-TG2]) has changed the epidemiology of coeliac disease from being a rare to a frequent condition, with an expected prevalence of 1% in the worldwide population. Coeliac disease can be difficult to diagnose because symptoms vary from patient to patient, and the majority of patients who have coeliac disease remain undiagnosed. Small intestinal biopsy remains the gold standard for coeliac disease diagnosis, and a delayed diagnosis in the elderly can be considered a risk factor for complications. Complicated coeliac disease is not so frequent, but for those who have it, the prognosis is very poor, with a low rate of survival after 5 years.

Topics

Small Intestine & Nutrition

Published

2024

More Like This:

From Vienna to Berlin: What inspired us last year at UEG Week

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre Pradeep Mundre, Egle Dieninyte - Misiune

Mistakes in coeliac disease diagnosis and how to avoid them

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio Roberto De Giorgio, Giacomo Caio, Umberto Volta

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude C. Janneke van der Woude, Shannon Kanis

Complications in endoscopy with Srisha Hebbar Part 1

Complications in endoscopy with Srisha Hebbar Part 1

Pradeep Mundre Pradeep Mundre, Srisha Hebbar

Mistakes in enteral stenting and how to avoid them

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Adam R, et al. 2018 Annual report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293–1317. [Link]
2.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433–485. [Link]
3.
Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144–1165. [Link]
4.
Russo FP, Ferrarese A and Zanetto A. Recent advances in understanding and managing liver transplantation. F1000Res 2016; 5. [Link]
5.
Toniutto P, et al. Current challenges and future directions for liver transplantation. Liver Int 2017; 37: 317–327. [Link]
6.
European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402. [Link]
7.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64: 179–202. [Link]
8.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047–1081. [Link]
9.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154–181. [Link]
10.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. [Link]
11.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. [Link]
12.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70: 172–193. [Link]
13.
Burra P, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138–148. [Link]
14.
Testino G, et al. Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020; 52: 21–32. [Link]
15.
Kotlyar DS, et al. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103: 734–743. [Link]
16.
Donckier V, et al. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol 2014; 60: 866–871. [Link]
17.
Burra P and Germani G. Transplantation for acute alcoholic hepatitis. Clin Liver Dis 2017; 9: 141–143. [Link]
18.
Donnadieu-Rigole H, et al. Integration of an Addiction Team in a Liver Transplantation Center. Liver Transpl 2019; 25: 1611–1619. [Link]
19.
Erard-Poinsot D, et al. Natural history of recurrent alcohol-related cirrhosis after liver transplantation: fast and furious. Liver Transpl 2020; 26: 25–33. [Link]
20.
Lucey MR, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628–637. [Link]
21.
Burra P, et al. Long-term medical and psycho-social evaluation of patients undergoing orthotopic liver transplantation for alcoholic liver disease. Transpl Int 2000; 13 (Suppl 1): S174–S178. [Link]
22.
Tandon P, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009; 104: 1700–1706. [Link]
23.
Burra P, et al. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017; 49: 241–253. [Link]
24.
Mathurin P, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790–1800. [Link]
25.
Cross TJ, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382–1388. [Link]
26.
Lipshutz GS, et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775–781. [Link]
27.
Durand F, et al. Age and liver transplantation. J Hepatol 2019; 70: 745–758. [Link]
28.
Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357. [Link]
29.
Nair S, Verma S and Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105–109. [Link]
30.
Hakeem AR, et al. Increased morbidity in overweight and obese liver transplant recipients: a single–center experience of 1,325 patients from the United Kingdom. Liver Transpl 2013; 19: 551–562. [Link]
31.
Leonard J, et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667–672. [Link]
32.
Kim, HY and Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015; 21: 7637–7647. [Link]
33.
Ooi PH, et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019; 25: 1422–1438. [Link]
34.
Pinto Dos Santos D, et al. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. Eur J Gastroenterol Hepatol Epub ahead of print, November 8, 2019. doi: 10.1097/MEG.0000000000001552. [Link]
35.
Carey EJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23: 625–633. [Link]
36.
Lai JC, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66: 564–574. [Link]
37.
Berzigotti A, Saran U and Dufour J-F. Physical activity and liver diseases. Hepatology 2016; 63: 1026–1040. [Link]
38.
Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699. [Link]
39.
Costentin CE, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation? Hepatology 2019; 69: 1324–1336. [Link]
40.
Duvoux C, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986–994.e3. [Link]
41.
Cillo U, et al. A multistep consensus-based approach to organ allocation in liver transplantation: toward a 'blended principle model'. Am J Transplant 2015; 15: 2552–2561. [Link]
42.
Zanetto A, et al. Mortality in liver transplant recipients with portal vein thrombosis — an updated meta-analysis. Transpl Int 2018; 31: 1318–1329. [Link]
43.
Senzolo M, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol 2018; 9: 176. [Link]
44.
Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61: 660–667. [Link]
45.
D'Amico G, De Franchis R and Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599–612. [Link]
46.
Zanetto A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017; 49: 440–445. [Link]
47.
Rodriguez-Castro KI, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31: 34–42. [Link]
48.
Zanetto A and Senzolo M. Management of thrombosis in liver transplant candidate. In: Bezinover D and F Saner FH (Eds). Critical Care for Potential Liver Transplant Candidates. 2019; New York: Springer International Publishing. pp 119–146.
49.
Loffredo L, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153: 480–487.e1. [Link]
50.
Senzolo M, et al. Portal vein thrombosis in decompensated cirrhosis: rationale for treatment. Clin Transl Gastroenterol 2019; 10: e00026. [Link]
51.
Tripodi A and Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147–156. [Link]
52.
Lisman T, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53–61. [Link]
53.
Rijken DC, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116–2122. [Link]
54.
Russo FP, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int 2018; 38: 2210–2218. [Link]
55.
Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis 2016; 48: 455–467. [Link]
56.
Intagliata NM and Caldwell SH. Changes in hemostasis in liver disease. J Hepatol 2017; 67: 1332–1333. [Link]
57.
DeAngelis GA, et al. Bleeding risk and management in interventional procedures in chronic liver disease. J Vasc Interv Radiol 2016; 27: 1665–1674. [Link]
58.
O'Leary JG, et al. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology 2019; 157: 34–43.e1. [Link]
59.
Lisman, T. Interpreting hemostatic profiles assessed with viscoelastic tests in patients with cirrhosis. J Clin Gastroenterol 2020; 54: 389–391. [Link]
60.
Mallett S, et al. Thrombin generation tests and viscoelastic testing in cirrhosis: comparing apples and oranges? Eur J Anaesthesiol 2017; 34: 36–37. [Link]
61.
De Pietri L, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566–573. [Link]
62.
Lucey MR, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3–26. [Link]
63.
Watt KD and Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199–206. [Link]
64.
Madhwal S, et al. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl 2012; 18: 1140–1146. [Link]
65.
Desai S, Hong JC and Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors incidence and management. Liver Int 2010; 30: 948–957. [Link]
66.
Germani G, et al. Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. Dig Liver Dis 2020; 52: e46–e71 [Link]
67.
Bernal W, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013; 59: 74–80. [Link]
68.
Gimson AE, et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288–294. [Link]
69.
Bernal W, et al. Acute liver failure. Lancet 2010; 376: 190–201. [Link]

Abstract

Barrett’s oesophagus is a premalignant condition of the distal oesophagus predisposing to oesophageal adenocarcinoma. Given the potential for malignant progression and the poor prognosis of eosophageal adenocarcinoma when diagnosed at a symptomatic stage, patients with known Barrett oesophagus undergo regular endoscopic surveillance to detect neoplastic progression at an early and preferably endoscopically, treatable stage. Endoscopic management of early Barrett oesophagus neoplasia consists of a combination of endoscopic imaging, endoscopic resection and endoscopic ablation. Below we discuss a number of mistakes that are frequently made when managing Barrett oesophagus neoplasia and how to avoid them. Much of this discussion draws on existing guidelines (for background reading, check the ESGE Barrett oesophagus guideline), but in many instances the underlying evidence (even in the guideline) is missing and therefore many of our practically driven recommendations are based on common sense and our experience in this field.


Topics

Oesophagus

Citation

Verheij EPD, Pouw RE and Bergman JJ. Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them. UEG Education 2021; 21: 35–39.

Published

2021

More Like This:

From Vienna to Berlin: What inspired us last year at UEG Week

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre Pradeep Mundre, Egle Dieninyte - Misiune

Mistakes in coeliac disease diagnosis and how to avoid them

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio Roberto De Giorgio, Giacomo Caio, Umberto Volta

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude C. Janneke van der Woude, Shannon Kanis

Complications in endoscopy with Srisha Hebbar Part 1

Complications in endoscopy with Srisha Hebbar Part 1

Pradeep Mundre Pradeep Mundre, Srisha Hebbar

Mistakes in enteral stenting and how to avoid them

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude, Shannon Kanis

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Adam R, et al. 2018 Annual report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293–1317. [Link]
2.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433–485. [Link]
3.
Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144–1165. [Link]
4.
Russo FP, Ferrarese A and Zanetto A. Recent advances in understanding and managing liver transplantation. F1000Res 2016; 5. [Link]
5.
Toniutto P, et al. Current challenges and future directions for liver transplantation. Liver Int 2017; 37: 317–327. [Link]
6.
European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402. [Link]
7.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64: 179–202. [Link]
8.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047–1081. [Link]
9.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154–181. [Link]
10.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. [Link]
11.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. [Link]
12.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70: 172–193. [Link]
13.
Burra P, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138–148. [Link]
14.
Testino G, et al. Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020; 52: 21–32. [Link]
15.
Kotlyar DS, et al. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103: 734–743. [Link]
16.
Donckier V, et al. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol 2014; 60: 866–871. [Link]
17.
Burra P and Germani G. Transplantation for acute alcoholic hepatitis. Clin Liver Dis 2017; 9: 141–143. [Link]
18.
Donnadieu-Rigole H, et al. Integration of an Addiction Team in a Liver Transplantation Center. Liver Transpl 2019; 25: 1611–1619. [Link]
19.
Erard-Poinsot D, et al. Natural history of recurrent alcohol-related cirrhosis after liver transplantation: fast and furious. Liver Transpl 2020; 26: 25–33. [Link]
20.
Lucey MR, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628–637. [Link]
21.
Burra P, et al. Long-term medical and psycho-social evaluation of patients undergoing orthotopic liver transplantation for alcoholic liver disease. Transpl Int 2000; 13 (Suppl 1): S174–S178. [Link]
22.
Tandon P, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009; 104: 1700–1706. [Link]
23.
Burra P, et al. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017; 49: 241–253. [Link]
24.
Mathurin P, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790–1800. [Link]
25.
Cross TJ, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382–1388. [Link]
26.
Lipshutz GS, et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775–781. [Link]
27.
Durand F, et al. Age and liver transplantation. J Hepatol 2019; 70: 745–758. [Link]
28.
Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357. [Link]
29.
Nair S, Verma S and Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105–109. [Link]
30.
Hakeem AR, et al. Increased morbidity in overweight and obese liver transplant recipients: a single–center experience of 1,325 patients from the United Kingdom. Liver Transpl 2013; 19: 551–562. [Link]
31.
Leonard J, et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667–672. [Link]
32.
Kim, HY and Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015; 21: 7637–7647. [Link]
33.
Ooi PH, et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019; 25: 1422–1438. [Link]
34.
Pinto Dos Santos D, et al. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. Eur J Gastroenterol Hepatol Epub ahead of print, November 8, 2019. doi: 10.1097/MEG.0000000000001552. [Link]
35.
Carey EJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23: 625–633. [Link]
36.
Lai JC, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66: 564–574. [Link]
37.
Berzigotti A, Saran U and Dufour J-F. Physical activity and liver diseases. Hepatology 2016; 63: 1026–1040. [Link]
38.
Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699. [Link]
39.
Costentin CE, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation? Hepatology 2019; 69: 1324–1336. [Link]
40.
Duvoux C, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986–994.e3. [Link]
41.
Cillo U, et al. A multistep consensus-based approach to organ allocation in liver transplantation: toward a 'blended principle model'. Am J Transplant 2015; 15: 2552–2561. [Link]
42.
Zanetto A, et al. Mortality in liver transplant recipients with portal vein thrombosis — an updated meta-analysis. Transpl Int 2018; 31: 1318–1329. [Link]
43.
Senzolo M, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol 2018; 9: 176. [Link]
44.
Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61: 660–667. [Link]
45.
D'Amico G, De Franchis R and Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599–612. [Link]
46.
Zanetto A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017; 49: 440–445. [Link]
47.
Rodriguez-Castro KI, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31: 34–42. [Link]
48.
Zanetto A and Senzolo M. Management of thrombosis in liver transplant candidate. In: Bezinover D and F Saner FH (Eds). Critical Care for Potential Liver Transplant Candidates. 2019; New York: Springer International Publishing. pp 119–146.
49.
Loffredo L, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153: 480–487.e1. [Link]
50.
Senzolo M, et al. Portal vein thrombosis in decompensated cirrhosis: rationale for treatment. Clin Transl Gastroenterol 2019; 10: e00026. [Link]
51.
Tripodi A and Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147–156. [Link]
52.
Lisman T, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53–61. [Link]
53.
Rijken DC, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116–2122. [Link]
54.
Russo FP, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int 2018; 38: 2210–2218. [Link]
55.
Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis 2016; 48: 455–467. [Link]
56.
Intagliata NM and Caldwell SH. Changes in hemostasis in liver disease. J Hepatol 2017; 67: 1332–1333. [Link]
57.
DeAngelis GA, et al. Bleeding risk and management in interventional procedures in chronic liver disease. J Vasc Interv Radiol 2016; 27: 1665–1674. [Link]
58.
O'Leary JG, et al. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology 2019; 157: 34–43.e1. [Link]
59.
Lisman, T. Interpreting hemostatic profiles assessed with viscoelastic tests in patients with cirrhosis. J Clin Gastroenterol 2020; 54: 389–391. [Link]
60.
Mallett S, et al. Thrombin generation tests and viscoelastic testing in cirrhosis: comparing apples and oranges? Eur J Anaesthesiol 2017; 34: 36–37. [Link]
61.
De Pietri L, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566–573. [Link]
62.
Lucey MR, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3–26. [Link]
63.
Watt KD and Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199–206. [Link]
64.
Madhwal S, et al. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl 2012; 18: 1140–1146. [Link]
65.
Desai S, Hong JC and Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors incidence and management. Liver Int 2010; 30: 948–957. [Link]
66.
Germani G, et al. Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. Dig Liver Dis 2020; 52: e46–e71 [Link]
67.
Bernal W, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013; 59: 74–80. [Link]
68.
Gimson AE, et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288–294. [Link]
69.
Bernal W, et al. Acute liver failure. Lancet 2010; 376: 190–201. [Link]

Abstract

Inflammatory bowel disease (IBD) is a chronic relapsing gastrointestinal disease, often affecting young people during their fertile years. The chronic character of IBD means that lifelong medical treatment is often required. As such, it is not surprising that questions often arise about fertility and pregnancy in patients with IBD. The most important risk factor for adverse pregnancy outcomes in IBD patients is the presence of disease activity during pregnancy. Indeed, negative pregnancy outcomes (e.g. spontaneous abortion, preterm delivery and low birth weight) are associated with disease activity at the time of conception and during pregnancy.

Topics

IBD Primary Care

Citation

 Cite this article as: Kanis SL and van der Woude CJ. Mistakes in inflammatory bowel disease and reproduction and how to avoid them. UEG Education 2016: 16: 20–23.

Published

2024

More Like This:

From Vienna to Berlin: What inspired us last year at UEG Week

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre Pradeep Mundre, Egle Dieninyte - Misiune

Mistakes in coeliac disease diagnosis and how to avoid them

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio Roberto De Giorgio, Giacomo Caio, Umberto Volta

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude C. Janneke van der Woude, Shannon Kanis

Complications in endoscopy with Srisha Hebbar Part 1

Complications in endoscopy with Srisha Hebbar Part 1

Pradeep Mundre Pradeep Mundre, Srisha Hebbar

Mistakes in enteral stenting and how to avoid them

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

UEG Podcast Episode
UEG Podcast
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Complications in endoscopy with Srisha Hebbar Part 1

Srisha Hebbar, Pradeep Mundre

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

Abstract

Topics

Endoscopy

Published

2025

More Like This:

From Vienna to Berlin: What inspired us last year at UEG Week

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre Pradeep Mundre, Egle Dieninyte - Misiune

Mistakes in coeliac disease diagnosis and how to avoid them

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio Roberto De Giorgio, Giacomo Caio, Umberto Volta

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude C. Janneke van der Woude, Shannon Kanis

Complications in endoscopy with Srisha Hebbar Part 1

Complications in endoscopy with Srisha Hebbar Part 1

Pradeep Mundre Pradeep Mundre, Srisha Hebbar

Mistakes in enteral stenting and how to avoid them

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

UEG Mistakes In Articles
Share via Email Share on Facebook Share on X Share on LinkedIn Share on Bluesky

Log in to continue.

This content is part of Gutflix. Log in with your myUEG account, or create one free, to watch it.

Log In Create a free account

Not sure what you can access? Learn more about account types.

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

Summary

AI Generated

Summary is not available for this content yet.

Download PDF

Was this helpful?

Thanks for your feedback.

This summary was generated by an AI large language model based on the content transcript. It is for informational purposes only and should not be considered a substitute for clinical judgment. Always rely on your professional expertise and the full clinical context when making clinical decisions.

References

Mistakes
References
Mistake 1 Mistake 2 Mistake 3 Mistake 4 Mistake 5 Mistake 6 Mistake 7 Mistake 8 Mistake 9 Mistake 10
1.
Adam R, et al. 2018 Annual report of the European Liver Transplant Registry (ELTR) – 50-year evolution of liver transplantation. Transpl Int 2018; 31: 1293–1317. [Link]
2.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Liver transplantation. J Hepatol 2016; 64: 433–485. [Link]
3.
Martin P, et al. Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology 2014; 59: 1144–1165. [Link]
4.
Russo FP, Ferrarese A and Zanetto A. Recent advances in understanding and managing liver transplantation. F1000Res 2016; 5. [Link]
5.
Toniutto P, et al. Current challenges and future directions for liver transplantation. Liver Int 2017; 37: 317–327. [Link]
6.
European Association for the Study of the Liver, European Association for the Study of Diabetes and European Association for the Study of Obesity. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. J Hepatol 2016; 64: 1388–1402. [Link]
7.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J Hepatol 2016; 64: 179–202. [Link]
8.
European Association for the Study of the Liver. EASL Clinical Practical Guidelines on the management of acute (fulminant) liver failure. J Hepatol 2017; 66: 1047–1081. [Link]
9.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of alcohol-related liver disease. J Hepatol 2018; 69: 154–181. [Link]
10.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol 2018; 69: 406–460. [Link]
11.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182–236. [Link]
12.
European Association for the Study of the Liver. EASL Clinical Practice Guidelines on nutrition in chronic liver disease. J Hepatol 2019; 70: 172–193. [Link]
13.
Burra P, et al. Liver transplantation for alcoholic liver disease in Europe: a study from the ELTR (European Liver Transplant Registry). Am J Transplant 2010; 10: 138–148. [Link]
14.
Testino G, et al. Management of end-stage alcohol-related liver disease and severe acute alcohol-related hepatitis: position paper of the Italian Society on Alcohol (SIA). Dig Liver Dis 2020; 52: 21–32. [Link]
15.
Kotlyar DS, et al. A critical review of candidacy for orthotopic liver transplantation in alcoholic liver disease. Am J Gastroenterol 2008; 103: 734–743. [Link]
16.
Donckier V, et al. Ethical considerations regarding early liver transplantation in patients with severe alcoholic hepatitis not responding to medical therapy. J Hepatol 2014; 60: 866–871. [Link]
17.
Burra P and Germani G. Transplantation for acute alcoholic hepatitis. Clin Liver Dis 2017; 9: 141–143. [Link]
18.
Donnadieu-Rigole H, et al. Integration of an Addiction Team in a Liver Transplantation Center. Liver Transpl 2019; 25: 1611–1619. [Link]
19.
Erard-Poinsot D, et al. Natural history of recurrent alcohol-related cirrhosis after liver transplantation: fast and furious. Liver Transpl 2020; 26: 25–33. [Link]
20.
Lucey MR, et al. Minimal criteria for placement of adults on the liver transplant waiting list: a report of a national conference organized by the American Society of Transplant Physicians and the American Association for the Study of Liver Diseases. Liver Transpl Surg 1997; 3: 628–637. [Link]
21.
Burra P, et al. Long-term medical and psycho-social evaluation of patients undergoing orthotopic liver transplantation for alcoholic liver disease. Transpl Int 2000; 13 (Suppl 1): S174–S178. [Link]
22.
Tandon P, et al. A shorter duration of pre-transplant abstinence predicts problem drinking after liver transplantation. Am J Gastroenterol 2009; 104: 1700–1706. [Link]
23.
Burra P, et al. Common issues in the management of patients in the waiting list and after liver transplantation. Dig Liver Dis 2017; 49: 241–253. [Link]
24.
Mathurin P, et al. Early liver transplantation for severe alcoholic hepatitis. N Engl J Med 2011; 365(19): 1790–1800. [Link]
25.
Cross TJ, et al. Liver transplantation in patients over 60 and 65 years: an evaluation of long-term outcomes and survival. Liver Transpl 2007; 13: 1382–1388. [Link]
26.
Lipshutz GS, et al. Outcome of liver transplantation in septuagenarians: a single-center experience. Arch Surg 2007; 142: 775–781. [Link]
27.
Durand F, et al. Age and liver transplantation. J Hepatol 2019; 70: 745–758. [Link]
28.
Chalasani N, et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 2018; 67: 328–357. [Link]
29.
Nair S, Verma S and Thuluvath PJ. Obesity and its effect on survival in patients undergoing orthotopic liver transplantation in the United States. Hepatology 2002; 35: 105–109. [Link]
30.
Hakeem AR, et al. Increased morbidity in overweight and obese liver transplant recipients: a single–center experience of 1,325 patients from the United Kingdom. Liver Transpl 2013; 19: 551–562. [Link]
31.
Leonard J, et al. The impact of obesity on long-term outcomes in liver transplant recipients-results of the NIDDK liver transplant database. Am J Transplant 2008; 8: 667–672. [Link]
32.
Kim, HY and Jang JW. Sarcopenia in the prognosis of cirrhosis: Going beyond the MELD score. World J Gastroenterol 2015; 21: 7637–7647. [Link]
33.
Ooi PH, et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019; 25: 1422–1438. [Link]
34.
Pinto Dos Santos D, et al. Sarcopenia as prognostic factor for survival after orthotopic liver transplantation. Eur J Gastroenterol Hepatol Epub ahead of print, November 8, 2019. doi: 10.1097/MEG.0000000000001552. [Link]
35.
Carey EJ, et al. A multicenter study to define sarcopenia in patients with end-stage liver disease. Liver Transpl 2017; 23: 625–633. [Link]
36.
Lai JC, et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 2017; 66: 564–574. [Link]
37.
Berzigotti A, Saran U and Dufour J-F. Physical activity and liver diseases. Hepatology 2016; 63: 1026–1040. [Link]
38.
Mazzaferro V, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693–699. [Link]
39.
Costentin CE, et al. Is it time to reconsider the Milan criteria for selecting patients with hepatocellular carcinoma for deceased-donor liver transplantation? Hepatology 2019; 69: 1324–1336. [Link]
40.
Duvoux C, et al. Liver transplantation for hepatocellular carcinoma: a model including alpha-fetoprotein improves the performance of Milan criteria. Gastroenterology 2012; 143: 986–994.e3. [Link]
41.
Cillo U, et al. A multistep consensus-based approach to organ allocation in liver transplantation: toward a 'blended principle model'. Am J Transplant 2015; 15: 2552–2561. [Link]
42.
Zanetto A, et al. Mortality in liver transplant recipients with portal vein thrombosis — an updated meta-analysis. Transpl Int 2018; 31: 1318–1329. [Link]
43.
Senzolo M, et al. Long-term outcome of splanchnic vein thrombosis in cirrhosis. Clin Transl Gastroenterol 2018; 9: 176. [Link]
44.
Nery F, et al. Causes and consequences of portal vein thrombosis in 1,243 patients with cirrhosis: results of a longitudinal study. Hepatology 2015; 61: 660–667. [Link]
45.
D'Amico G, De Franchis R and Cooperative Study Group. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology 2003; 38: 599–612. [Link]
46.
Zanetto A, et al. Thromboelastometry hypercoagulable profiles and portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma. Dig Liver Dis 2017; 49: 440–445. [Link]
47.
Rodriguez-Castro KI, et al. A prediction model for successful anticoagulation in cirrhotic portal vein thrombosis. Eur J Gastroenterol Hepatol 2019; 31: 34–42. [Link]
48.
Zanetto A and Senzolo M. Management of thrombosis in liver transplant candidate. In: Bezinover D and F Saner FH (Eds). Critical Care for Potential Liver Transplant Candidates. 2019; New York: Springer International Publishing. pp 119–146.
49.
Loffredo L, et al. Effects of anticoagulants in patients with cirrhosis and portal vein thrombosis: a systematic review and meta-analysis. Gastroenterology 2017; 153: 480–487.e1. [Link]
50.
Senzolo M, et al. Portal vein thrombosis in decompensated cirrhosis: rationale for treatment. Clin Transl Gastroenterol 2019; 10: e00026. [Link]
51.
Tripodi A and Mannucci PM. The coagulopathy of chronic liver disease. N Engl J Med 2011; 365: 147–156. [Link]
52.
Lisman T, et al. Elevated levels of von Willebrand Factor in cirrhosis support platelet adhesion despite reduced functional capacity. Hepatology 2006; 44: 53–61. [Link]
53.
Rijken DC, et al. Evidence for an enhanced fibrinolytic capacity in cirrhosis as measured with two different global fibrinolysis tests. J Thromb Haemost 2012; 10: 2116–2122. [Link]
54.
Russo FP, et al. Reversal of hypercoagulability in patients with HCV-related cirrhosis after treatment with direct-acting antivirals. Liver Int 2018; 38: 2210–2218. [Link]
55.
Under the auspices of the Italian Association for the Study of Liver Diseases (AISF) and the Italian Society of Internal Medicine (SIMI). Hemostatic balance in patients with liver cirrhosis: Report of a consensus conference. Dig Liver Dis 2016; 48: 455–467. [Link]
56.
Intagliata NM and Caldwell SH. Changes in hemostasis in liver disease. J Hepatol 2017; 67: 1332–1333. [Link]
57.
DeAngelis GA, et al. Bleeding risk and management in interventional procedures in chronic liver disease. J Vasc Interv Radiol 2016; 27: 1665–1674. [Link]
58.
O'Leary JG, et al. AGA Clinical Practice Update: coagulation in cirrhosis. Gastroenterology 2019; 157: 34–43.e1. [Link]
59.
Lisman, T. Interpreting hemostatic profiles assessed with viscoelastic tests in patients with cirrhosis. J Clin Gastroenterol 2020; 54: 389–391. [Link]
60.
Mallett S, et al. Thrombin generation tests and viscoelastic testing in cirrhosis: comparing apples and oranges? Eur J Anaesthesiol 2017; 34: 36–37. [Link]
61.
De Pietri L, et al. Thrombelastography-guided blood product use before invasive procedures in cirrhosis with severe coagulopathy: A randomized, controlled trial. Hepatology 2016; 63: 566–573. [Link]
62.
Lucey MR, et al. Long-term management of the successful adult liver transplant: 2012 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Liver Transpl 2013; 19: 3–26. [Link]
63.
Watt KD and Charlton MR. Metabolic syndrome and liver transplantation: a review and guide to management. J Hepatol 2010; 53: 199–206. [Link]
64.
Madhwal S, et al. Is liver transplantation a risk factor for cardiovascular disease? A meta-analysis of observational studies. Liver Transpl 2012; 18: 1140–1146. [Link]
65.
Desai S, Hong JC and Saab S. Cardiovascular risk factors following orthotopic liver transplantation: predisposing factors incidence and management. Liver Int 2010; 30: 948–957. [Link]
66.
Germani G, et al. Role of a dedicated referral system for patients with liver disease and potential indication for liver transplantation: prospective data from a single centre experience. Dig Liver Dis 2020; 52: e46–e71 [Link]
67.
Bernal W, et al. Lessons from look-back in acute liver failure? A single centre experience of 3300 patients. J Hepatol 2013; 59: 74–80. [Link]
68.
Gimson AE, et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology 1986; 6: 288–294. [Link]
69.
Bernal W, et al. Acute liver failure. Lancet 2010; 376: 190–201. [Link]

Abstract

Indications include stenosis (oesophageal and colonic) and gastric outlet obstruction

Topics

Radiology & Imaging Surgery

Citation

Veld JV, Fockens P and van Hooft JE. Mistakes in enteral stenting and how to avoid them. UEG Education 2019; 19: 5–8

Published

2019

More Like This:

From Vienna to Berlin: What inspired us last year at UEG Week

From Vienna to Berlin: What inspired us last year at UEG Week

Pradeep Mundre Pradeep Mundre, Egle Dieninyte - Misiune

Mistakes in coeliac disease diagnosis and how to avoid them

Mistakes in coeliac disease diagnosis and how to avoid them

Roberto De Giorgio Roberto De Giorgio, Giacomo Caio, Umberto Volta

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Mistakes in endoscopic treatment of Barrett oesophagus neoplasia and how to avoid them

Jacques J. Bergman Jacques J. Bergman, Roos E. Pouw, Eva Verheij

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

Mistakes in inflammatory bowel disease and reproduction and how to avoid them

C. Janneke van der Woude C. Janneke van der Woude, Shannon Kanis

Complications in endoscopy with Srisha Hebbar Part 1

Complications in endoscopy with Srisha Hebbar Part 1

Pradeep Mundre Pradeep Mundre, Srisha Hebbar

Mistakes in enteral stenting and how to avoid them

Mistakes in enteral stenting and how to avoid them

Jeanin van Hooft Jeanin van Hooft, Paul Fockens, Joyce Valerie Veld

The global reference point for the digestive health community

Platform Publisher

United European Gastroenterology

Wickenburggasse 1 1080 Vienna, Austria

Contact us

support@ueg.eu

ueg.eu

T: +43 1 997 1639

Legal

Terms & Conditions

Imprint

Privacy Policy

Explore

My Bookmarks

My recommendations

My fields of interest

© 2026 United European Gastroenterology

Change fields of interest

These fields are selected based on the interests in your myUEG profile.
Click the item to unselect it. You can select multiple items.